Обратная связь1. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152.
2. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
3. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J
Med. 2015;372(22):2127–35.
4. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and
adolescence. Am J Epidemiol. 1974;99(2):131–8.
5. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
6. Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period
distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol.
2011;40(4):964–70.7. Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт]
(http://www.who.int/tb/strategy/en/ по состоянию на 31 марта 2021 г.).
8. Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт];
2013 (https://www.who.int/tb/post2015_strategy/en/ по состоянию на 31 марта 2021 г.).
9. Framework towards tuberculosis elimination in low-Incidence countries. Geneva: World Health Organization;
2014 (http://www.ncbi.nlm.nih.gov/books/NBK254256/, accessed 15 March 2020).
10. Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (http://www.who.int/tb/
publications/global_report/en/, accessed 15 March 2020).
11. Политическая декларация заседания высокого уровня Генеральной Ассамблеи по борьбе
с туберкулезом. Семьдесят третья сессия Генеральной ассамблеи ООН; 2018 https://undocs.org/ru/A/
RES/73/3, по состоянию на 31 марта 2021 г.).
12. WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment. Geneva: World Health
Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf,
accessed 15 March 2020).
13. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies.
Geneva: World Health Organization; 2010 (https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_
full_web.pdf, accessed 15 March 2020).
14. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of
latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.
15. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, Vries G de, Diel R, et al. Towards tuberculosis elimination:
an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52.
16. Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization
and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis.
J Int AIDS Soc. 2016;19(1):20714.
17. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy
on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the
Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
18. Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with
HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/
bitstream/handle/10665/44472/9789241500708_eng.pdf, accessed 15 March 2020).
19. Bruins WS, Leth F van. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected
individuals: a systematic review. Infect Dis. 2017;49(3):161–9.
20. Cotton M, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed
infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–7.
21. Cranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, et al. High
prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants: Pediatr Infect Dis J. 2014;33(4):401–6.
22. Kali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case
finding for tuberculosis. J Acquir Immune Defic Syndr 1999. 2006;42(3):379–81.
23. Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course
(6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13(14):1899–904.
24. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with
HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Lancet. 1999;353(9167):1843–7.
25. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with
multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med.
1993;328(16):1137–44.
26. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et al. Recurrent TB: relapse
or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–26.
27. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection
on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
28. Chaisson RE, Churchyard GJ. Recurrent tuberculosis – relapse, reinfection and HIV. J Infect Dis.
2010;201(5):653–5.
29. Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors.
London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrenttuberculosis-relapse-versus-reinfection-and-related-risk-factors, accessed 15 March 2020).
30. Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health
Organization; 2013 (https://www.who.int/tb/tbscreening/en/, accessed 15 March 2020).
31. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middleincome countries. Geneva: World Health Organization; 2012 (https://www.who.int/tb/publications/2012/
contact_investigation2012/en/, accessed 15 March 2020).
32. WHO Guidelines on tuberculosis infection prevention and control, 2019 update Geneva: World Health
Organization; 2019 (https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infectionprevention-2019/en/, accessed 15 March 2020).
33. Политика ВОЗ в отношении сотрудничества в области ТБ/ВИЧ. Руководящие принципы для
национальных программ и других заинтересованных сторон. Женева: Всемирная организация
здравоохранения; 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_eng_Annexes.pdf,
по состоянию на 31 марта 2021 г.).
34. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and metaanalysis. Eur Respir J. 2013;41(1):140–156.
35. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people
with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and metaanalysis. Lancet Infect Dis. 2008;8(6):359–368.
36. Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of identifying household contacts
of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease.
Clin Infect Dis. 2020; 70(3):425–35.
37. Lung T, Marks GB, Nhung NV, Anh NT, Hoa NLP, Anh LTN, et al. Household contact investigation for the
detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health.
2019;7(3):e376–84.
38. Sulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimb A, et al. Implementation of tuberculosis
prevention for exposed children, Burkina Faso. Bull World Health Organ. 2018;(96):386–92.
39. Prevent TB: a mobile app to support programmatic management of LTBI. Geneva: World Health Organization;
2020 (https://www.who.int/tb/prevent-tb-digital-platform/en/, по состоянию на 31 марта 2021 г.).
40. Обновленное сводное руководство по программному ведению случаев латентной туберкулезной
инфекции. Женева: Всемирная организация здравоохранения; 2018 (http://www.who.int/tb/
publications/2018/latent-tuberculosis-infection/en/, по состоянию на 31 марта 2021 г.).
41. Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance
on programmatic approaches. Geneva: World Health Organization; 2016 (who.int/tb/publications/chestradiography/en/, accessed 15 March 2020).
42. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, et al. Costs and consequences
of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med.
2011;183(8):1103–11.
43. TB Elimination. Interferon-Gamma Release Assays (IGRAs) – Blood tests for TB infection. Atlanta: Centre for
Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, accessed
15 March 2020).
44. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons.
Cochrane Database Syst Rev. 2010;(1) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.
CD000171.pub3/abstract, accessed 15 March 2020).
45. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis
infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–55.
46. Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis
preventive treatment: a systematic review Int J Tuberc Lung Dis 2018;22(12):1422–28.
47. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared
to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst
Rev 2013;7 (DOI: 10.1002/14651858.CD007545.pub2, accessed 16 March 2020).
48. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine
and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic
review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.
49. Руководство по ведению пациентов с латентной туберкулезной инфекцией. Женева: Всемирная
организация здравоохранения; 2015 (https://apps.who.int/medicinedocs/documents/s21682en/
s21682en.pdf, по состоянию на 31 марта 2021 г.).
50. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World
Health Organization; 2014 (https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf,
accessed 16 March 2020).
51. January 2020. Medicines catalogue. Geneva: Global Drug Facility; 2020 (http://www.stoptb.org/assets/
documents/gdf/drugsupply/GDFMedicinesCatalog.pdf, accessed 16 March 2020).
52. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine
and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
53. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine
and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS.
2016;30(10):1607–15.
54. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine
plus isoniazid to prevent hiv-related tuberculosis. N Engl J Med. 2019;380(11):1001–11.
55. Landmark deal secures significant discount on price of medicine to prevent TB. Press realease 2019.
Unitaid [веб-сайт] (https://unitaid.org/news-blog/landmark-deal-secures-significant-discount-on-priceof-medicine- to-prevent-tb/#en, accessed 16 March 2020.
56. Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection Revisiting and revising
concepts. Tuberculosis. 2015;95(4):373–84.
57. Catalyzing pediatric tuberculosis innovations (CaP TB): Short-course treatment regimens to prevent TB: 3HP
and 3RH. Technical Brief. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/catalyzing-pediatrictuberculosis-innovations-cap-tb-short-course-treatment-regimens-to-prevent-tb-3hp-and-3rh/, accessed
16 March 2020).
58. TPT implementation tools. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/3hp-documents/,
по состоянию на 31 марта 2021 г.).
59. Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191–6.
60. Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc.
1954;70(3):430–41.
61. Oestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid.
Am Rev Tuberc. 1954;70(3):504–8.
62. Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative
therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–9.
63. Money GL. Isoniazid neuropathies in malnourished tuberculous patients. J Trop Med Hyg. 1959;62(8):198–202.
64. Toman K, Frieden TR. Toman’s tuberculosis: case detection, treatment and monitoring; questions and
answers. 2nd edition. Geneva: World Health Organization; 2004.
65. McCune R, Deuschle K, Mcdermott W. The delayed appearance of isoniazid antagonism by pyridoxine in
vivo. Am Rev Tuberc Pulm Dis. 1957;76(6):1100–5.
66. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from
pyridoxine abuse. N Engl J Med. 1983;309(8):445–8.
67. Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and
excess. J Clin Neuromuscul Dis. 2014;16(1):25–31.
68. Sotgiu G, Matteelli A, Getahun H, Girardi E, Schepisi MS, Centis R, et al. Monitoring toxicity in individuals
receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir
J. 2015;45(4):1170–3.
69. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid
preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ.
1982;60(4):555–64.
70. Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis.
1970;101(5):780–2.
71. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine
months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.
72. Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion
in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis
infection. Clin Infect Dis. 2017;65(7):1085–93.
73. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent
Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir
J. 2015;46(6):1563–76.
74. Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World
Health Organization; 2017 (http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf,
accessed 18 March 2020).
75. Leveraging differentiated ART delivery models for stable clients to scale up TB preventive therapy. Differentiated
Service Delivery [Supplement]. Geneva: International AIDS Society (https://differentiatedservicedelivery.org/
Portals/0/adam/Content/3qTmUzah5kWCdeEogdiJ5A/File/IAS%20TPT%20supplement%208-Pager%20
DIGITAL.pdf, accessed 18 March 2020).
76. Differentiated models of delivering HIV care: Perspectives from people living with HIV and health care
workers in 7 African countries. ICAP HIV learning network_the CQUIN project for differentaited service
delivery [веб-сайт] (https://cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-ofdelivering-hiv-care//, accessed 18 March 2020).
77. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence
and mortality among HIV-Infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis.
2007;45(2):241–9.
78. Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes
in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso
Study. Clin Infect Dis. 2018;66(6):921–9.
79. Isoniazid tablet, USP. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/
drugsatfda_docs/label/2016/008678s028lbl.pdf, accessed 18 March 2020).
80. Rifadin® (rifampin capsules USP) and Rifadin® IV (rifampin for injection USP). Maryland: U.S. Food and
Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050
627s012lbl.pdf, accessed 18 March 2020).
81. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy
in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46.
82. Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics
of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob
Agents Chemother. 2015;60(3):1234–41.
83. Partosch F, Mielke H, Stahlmann R, Gundert-Remy U. Exposure of nursed infants to maternal treatment
with ethambutol and rifampicin. Basic Clin Pharmacol Toxicol. 2018;123(2):213–20.
84. Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, et al. Pharmacokinetics and
pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment
for HIV and TB: Potential concern for standard dosing frequency. Clin Infect Dis 2019; ciz863. doi: 10.1093/
cid/ciz863, accessed 18 March 2020).
85. Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy,
hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium
tuberculosis. Clin Infect Dis. 2001;33(10):1687–91.
86. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African
antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B: AIDS. 2007;21(10):1301–8.
87. McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin
plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother.
2017;72(7):2028–34.
88. Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential
for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ.
2019;367:l5894.
89. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent
tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7.
90. Ahmed A, Lutchman GA, Kwo PY. Drug–drug interactions in hepatitis C virus treatment: Do they really
matter? Clin Liver Dis. 2017;10(5):111–5.
91. Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A pharmacology perspective of
simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019 Oct 7;
AAC.01215–19. doi: 10.1128/AAC.01215–19, accessed 18 March 2020).
92. Friedland G. Infectious disease co-morbidities adversely affecting substance users with HIV: hepatitis C
and tuberculosis. J Acquir Immune Defic Syndr 2010;55(Suppl1):S37–42.
93. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce
opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34.
94. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis.
2009;48(1):72–82.
95. Mike F. An activist’s guide to rifapentine for the treatment of TB infection. New York: Treatment Action
Group; 2019 (https://www.treatmentactiongroup.org/publication/an-activists-guide-to-rifapentine-forthe-treatment-of-tb-infection//, accessed 18 March 2020).
96. Aquinas SM, Allan WGL, Horsfall PAL, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and
intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71.
97. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–6.
98. Weiner M, Savic RM, Kenzie WRM, Wing D, Peloquin CA, Engle M, et al. Rifapentine Pharmacokinetics and
tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis
infection. J Pediatr Infect Dis Soc. 2014;3(2):132–45.
99. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic
drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment
of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
100. Priftin (rifapentine) tablets. Highlights of prescribing information. Maryland: U.S. Food and Drug
Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf,
accessed 18 March 2020).
101. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection:
a network meta-analysis. Ann Intern Med. 2014;161(6):419–28.
102. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of
rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol
Drug Saf. 2018;27(6):557–66.
103. Pellagra and its prevention and control in major emergencies. Geneva: World Health Organization; 2000
(https://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/, accessed 18 March 2020).
104. Nursing guide for managing side effects to drug-resistant TB treatment. Berkeley: Curry international
tuberculosis centre; 2018 (https://www.currytbcenter.ucsf.edu/products/view/nursing-guide-managingside-effects-drug-resistant-tb-treatment, accessed 18 March 2020).
105. William JB, Keith G, Charles P. Comparative pharmacokinetics and pharmacodynamics of the rifamycin
antibacterials. Clin Pharmacokinet 2001;40:327–41.
106. HIV drug interaction checker. University of Liverpool [веб-сайт] (https://www.hiv-druginteractions.org/
checker, accessed 18 March 2020).
107. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). HIV/
AIDS. World Health Organization [веб-сайт]; 2018 (https://www.who.int/hiv/topics/treatment/dtg-tldbriefing-web/en/ accessed 18 March 2020).
108. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral
therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter,
noncomparative, open-label, randomized trial. Clin Infect Dis. 2020; 70(4):549–56.
109. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and
pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention.
Clin Infect Dis. 2015;61(8):1322–7.
110. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of
rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85.
111. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/
GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week
results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
112. Dooley KE, Churchyard G, Savic RM, Gupta A, Marzinke M, Zhang N, et al. Safety & PK of weekly rifapentine/
isoniazid (3HP) in adults with HIV on dolutegravir. Abstract 80. TB: From contact to cure and beyond.
Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (https://
www.croiconference.org/abstract/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir/,
accessed 18 March 2020).
113. López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, et al.
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
Clin Pharmacokinet. 2002;41(9):681–90.
114. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, et al. Relationship between weight, efavirenz
exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in
the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586–93.
115. Faren C, Dourumian S, Cantalloube C, Perrin L, Esposito V, Cierien-Puiseux I, et al. Rifapentine once-weekly
dosing effect on efavirenz, emtricitabine and tenofovir PKs. Abstract 493. Clinical Pharmacology of TB
and HCV Coinfection. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle,
Washington (http://www.croiconference.org/sites/default/files/abstracts/493.pdf, accessed 18 March 2020).
116. Medication Guide. Descovy® (emtricitabine and tenofovir alafenamide tablets). Foster City: Gilead Sciences
(https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_patient_pi.pdf, accessed 18
March 2020).
117. Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular
and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–8.
118. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy
on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the
Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
119. Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. Long-term protection from
isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis
setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015;60(4):639–45.
120. Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, et al. A trial of mass isoniazid
preventive therapy for tuberculosis control. N Engl J Med. 2014;370(4):301–10.
121. Kyaw NTT, Kumar AM, Kyaw KWY, Satyanarayana S, Magee MJ, Min AC, et al. IPT in people living with HIV
in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality. Int Union Tuberc Lung
Dis. 2019;23(3):322–30.
122. Wisaksana R, Hartantri Y, Lestari M, Azzahra D, Karjadi T, Yunihastuti E, et al. Benefit of isoniazid preventive
therapy to reduce incident TB, mortality and loss to follow-up in Indonesian five-years cohort. 22nd
International AIDS Conference (AIDS 2018); Amsterdam, Netherlands | 23–27 July 2018 (http://programme.
aids2018.org/Abstract/Abstract/8205).
123. Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis. 1962;86:810–22.
124. Shanaube K, Sismanidis C, Ayles H, Beyers N, Schaap A, Lawrence K-A, et al. Annual risk of tuberculous
infection using different methods in communities with a high prevalence of TB and HIV in Zambia and
South Africa. PLoS ONE. 2009;4(11):e7749.
125. Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the
bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827–30.
126. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent
adults? Int Union Tuberc Lung Dis. 1999;3(10):847–50.
127. Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected
persons. Cochrane Database Syst Rev. 1999 (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.
CD001363/full, accessed 18 March 2020).
128. Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine WL, Charalambous S, Martinson
NA, Yimer G. Effectiveness of 3HP annually vs. once for HIV-positive people: the WHIP3TB trial. In:
TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HIV TESTING. Boston, Massachusetts, USA; 2020.
(https://www.croiconference.org/sessions/effectiveness-3hp-annually-vs-once-hiv-positive-peoplewhip3tb-trial, accessed 18 March 2020).
129. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant
tuberculosis. Emerg Infect Dis. 2006;12(5):744–51.
130. den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection:
a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8): 1065–1071.
131. van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, et al. Tuberculosis outcomes
and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence
setting. AIDS. 2010;24(7):1051.
132. Best practice for the care of patients with tuberculosis. A guide for low-income countries. 2nd edition.
Paris: International Union Against Tuberculosis and Lung Disease; 2017. (https://theunion.org/what-we-do/
publications/technical/english/best-practice-2017-ENG.pdf accessed 18 March 2020).
133. Lutge EE, Wiysonge CS, Knight SE, Sinclair D, Volmink J. Incentives and enablers to improve adherence in
tuberculosis. Cochrane Database Syst Rev. 2015;(9):CD007952. doi: 10.1002/14651858.CD007952.pub3.
134. Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational Interviewing improves medication
adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016;31(8):929–40.
135. Ethics guidance for the implementation of the End TB Strategy. Geneva: World Health Organization; 2017
(http://www.who.int/tb/publications/2017/ethics-guidance/en/, accessed 18 March 2020).
136. Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology. 2010;15(4):603–22.
137. Chaisson RE, Golub JE. Preventing tuberculosis in people with HIV – no more excuses. Lancet Glob Health.
2017;5(11):e1048–9.
138. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations
for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection.
Morb Mortal Wkly Rep. 2018;67(25):723–6.
139. TB elimination. Tuberculin skin testing. Atlanta: Centre for Disease Control and Prevention; 2011 (https://
www.cdc.gov/tb/publications/factsheets/testing/skintesting.pdf, accessed 18 March 2020).
140. Morán-Mendoza O, Tello-Zavala MC, Rivera-Camarillo M, Ríos-Meza Y. Comparison of different methods
and times for reading the tuberculin skin test. Int J Tuberc Lung Dis. 2013;17(10):1273–8.
141. Zahrani KA, Jahdali HA, Menzies D. Does size matter? Utility of size of tuberculin reactions for the diagnosis
of mycobacterial disease. Am J Respir Crit Care Med. 2000;162(4):1419–22.
142. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic
Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice
Guidelines: Diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111–5.
143. Chaturvedi N, Cockcroft A. Tuberculosis screening in health service employees: who needs chest X-rays?
Occup Med. 1992;42(4):179–82.
144. Starke JR. Tuberculosis skin testing: new schools of thought. Pediatrics. 1996;98(1):123–5.
145. Nayak S, Acharjya B. Mantoux test and its interpretation. Indian Dermatol Online J. 2012;3(1):2–6.
146. Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb Mortal Wkly Rep.
2000;49(RR06):1–54.
147. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle. 1966;47(3):308.
148. Veening GJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin
conversion in young adults. Bull Int Union Tuberc. 1968;41:169–71.
149. Rothel JS, Jones SL, Corner LA, Cox JC, Wood PR. A sandwich enzyme immunoassay for bovine interferon-g
and its use for the detection of tuberculosis in cattle. Aust Vet J. 1990;67(4):134–7.
150. Converse PJ, Jones SL, Astemborski J, Vlahov D, Graham NMH. Comparison of a tuberculin interferon-g
assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J
Infect Dis. 1997;176(1):144–50.
151. Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis
infection. Int J Tuberc Lung Dis. 1998;2(6):443–50.
152. Kay AW, Islam SM, Wendorf K, Westenhouse J, Barry PM. Interferon-g release assay performance for
tuberculosis in childhood. Pediatrics. 2018;141(6):e20173918.
